Dra. María Natalia Gandur Quiroga, Coordinator in charge of the Urology Clinic Service at the Angel H. Roffo Institute, shared a recent article by Michael D. Staehler on X:
“Real-world outcomes of Cabozantinib in advanced renal cell carcinoma (aRCC) (CASSIOPE Study).
Key Findings: Cabozantinib showed effectiveness in real-world advanced RCC settings, with 8.3 months median PFS and a 74% 1-year OS rate.
Dose Adjustments: 77% required dose modifications for AEs, successfully optimizing treatment duration.
Manageable Safety: Safety profile consistent with clinical trials, with diarrhea, decreased appetite, and PPE syndrome as the most common AEs.
Real-world Impact: Demonstrates cabozantinib’s utility for patients excluded from clinical trials, reflecting broader applicability.”
Authors: Michael D. Staehler, Paul Hamberg, Pierre Bigot, Cristina Suárez, Philippe Barthelemy, Jean-Christophe Eymard, Mathieu Laramas, Naila Taguieva Pioger, Marine Gross-Goupil, Michael Rink, Cristina Masini, Rocco De Vivo, Pablo Gajate, Ashraf Azzabi and Giuseppe Procopio
More posts featuring Dra. María Natalia Gandur Quiroga.
